Picture loading failed.

Anti-PDCD1 therapeutic antibody (Pre-made Tislelizumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tislelizumab (BGB-A317) is a humanized monoclonal antibody directed against PD-1. It prevents PD-1 from binding to the ligands PD-L1 and PD-L2 (hence it is a checkpoint inhibitor). It is being investigated as a treatment for advanced solid tumors.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-581-1mg 1mg 3090
GMP-Bios-ab-581-10mg 10mg 21890
GMP-Bios-ab-581-100mg 100mg 148000
GMP-Bios-ab-581-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-PDCD1 therapeutic antibody (Pre-made Tislelizumab biosimilar,Whole mAb)
INN Name Tislelizumab
TargetPDCD1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure7bxa:BC:HL
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesBeiGene;Celgene Corporation
Conditions ApprovedHodgkin's disease;Urogenital cancer
Conditions ActiveGastric cancer;Liver cancer;Nasopharyngeal cancer;Non-small cell lung cancer;Oesophageal cancer;Lung cancer;Lymphoma;Solid tumours;Ovarian cancer;Renal cancer
Conditions Discontinuedna
Development Techna